MarketLens
Sign Up

Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals

7 months ago
SHARE THIS ON:

Why Did Servier Pay a 68% Premium for Day One Biopharmaceuticals

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

Edgewise Therapeutics raised ~$1.55B from selling sevasemten to Servier, extending its cash runway into the early 2030s. The deal self-funds late-stage development of EDG-7500, which showed robust Pha...
Stock News•3 months ago

Why This Pharmaceutical Stock Jumped Close to 100% This Week

Shares of a pharmaceutical stock surged nearly 100% this week after agreeing to be acquired by a larger sector firm.
Stock News•3 months ago

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.

Revolution Medicines, with a $40B market cap and no revenue, could launch its lead cancer drug within a year, potentially establishing new care standards in certain niches.

Breaking News

View All →

Top Headlines

View More →
Stock News•59 minutes ago

Jim Cramer sees major implications from SK Hynix's home-run quarter

Stock News•1 hour ago

Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow

Stock News•1 hour ago

Jim Cramer says these tech giants can weather market turbulence

Stock News•1 hour ago

Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Q3 Earnings and Revenues Miss Estimates